Literature DB >> 19528194

Sudden death and use of stimulant medications in youths.

Madelyn S Gould1, B Timothy Walsh, Jimmie Lou Munfakh, Marjorie Kleinman, Naihua Duan, Mark Olfson, Laurence Greenhill, Thomas Cooper.   

Abstract

OBJECTIVE: The authors sought to determine whether a significant association exists between the use of stimulants and the rare event of sudden unexplained death in children and adolescents.
METHOD: A matched case-control design was performed. Mortality data from 1985-1996 state vital statistics were used to identify 564 cases of sudden death occurring at ages 7 through 19 years across the United States along with a matched group of 564 young people who died as passengers in motor vehicle traffic accidents. The primary exposure measure was the presence of amphetamine, dextroamphetamine, methamphetamine, or methylphenidate according to informant reports or as noted in medical examiner records, toxicology results, or death certificates.
RESULTS: In 10 (1.8%) of the sudden unexplained deaths it was determined that the youths were taking stimulants, specifically methylphenidate; in contrast, use of stimulants was found in only two subjects in the motor vehicle accident comparison group (0.4%), with only one involving methylphenidate use. A significant association of stimulant use with sudden unexplained death emerged from the primary analysis, which was based on exact conditional logistic regression (odds ratio=7.4, 95% CI=1.4 to 74.9). A comprehensive series of sensitivity analyses yielded qualitatively similar findings.
CONCLUSIONS: This case-control study provides support for an association between the use of stimulants and sudden unexplained death among children and adolescents. Although sudden unexplained death is a rare event, this finding should be considered in the context of other data about the risk and benefit of stimulants in medical treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528194     DOI: 10.1176/appi.ajp.2009.09040472

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  58 in total

1.  ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Authors:  Laurel A Habel; William O Cooper; Colin M Sox; K Arnold Chan; Bruce H Fireman; Patrick G Arbogast; T Craig Cheetham; Virginia P Quinn; Sascha Dublin; Denise M Boudreau; Susan E Andrade; Pamala A Pawloski; Marsha A Raebel; David H Smith; Ninah Achacoso; Connie Uratsu; Alan S Go; Steve Sidney; Mai N Nguyen-Huynh; Wayne A Ray; Joe V Selby
Journal:  JAMA       Date:  2011-12-12       Impact factor: 56.272

2.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

3.  Cardiac risk assessment before the use of stimulant medications in children and youth.

Authors:  S A Bélanger; A E Warren; R M Hamilton; C Gray; R M Gow; S Sanatani; J M Côté; J Lougheed Frcpc; J Leblanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

4.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

5.  Taking the stress out of individualizing ADHD drug therapy.

Authors:  Melanie McLeod; Tessa Laubscher; Loren Regier; Brent Jensen
Journal:  Can Fam Physician       Date:  2009-09       Impact factor: 3.275

Review 6.  Adverse drug reactions - examples of detection of rare events using databases.

Authors:  Esther W Chan; Kirin Q L Liu; Celine S L Chui; Chor-Wing Sing; Lisa Y L Wong; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

7.  Pharmacologic intervention for attention-deficit hyperactivity disorder in preschoolers : is it justified?

Authors:  Jaswinder K Ghuman; Harinder S Ghuman
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 8.  Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis.

Authors:  Hui Liu; Wenjing Feng; Dongfeng Zhang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-08-24       Impact factor: 4.785

Review 9.  Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review.

Authors:  Bianca D Patel; Drew H Barzman
Journal:  Psychiatr Q       Date:  2013-12

10.  Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry.

Authors:  R Hamilton; C Gray; S A Bélanger; A E Warren; R M Gow; S Sanatani; J-M Côté; J Lougheed; J LeBlanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.